Universe Pharmaceuticals INC (NASDAQ:UPC) Short Interest Down 83.4% in April

Universe Pharmaceuticals INC (NASDAQ:UPC) was the target of a significant decline in short interest during the month of April. As of April 30th, there was short interest totaling 764 shares, a decline of 83.4% from the April 15th total of 4,610 shares. Based on an average daily trading volume, of 7,018 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.3% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Universe Pharmaceuticals in a report on Friday, May 1st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Universe Pharmaceuticals Stock Performance

NASDAQ:UPC traded up $0.07 on Wednesday, hitting $2.67. 12,079 shares of the stock were exchanged, compared to its average volume of 13,529. Universe Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $11.00. The company’s 50-day moving average price is $2.83 and its 200 day moving average price is $3.55.

Universe Pharmaceuticals (NASDAQ:UPC) last posted its earnings results on Thursday, January 29th. The company reported $0.69 earnings per share (EPS) for the quarter. The company had revenue of $8.92 billion for the quarter.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.